

## LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application:

1. **(Previously presented)** An antigen composition comprising tetramyristoyl cardiolipin and 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine.
2. **(Original)** The antigen composition of claim 1, further comprising cholesterol.
3. **(Currently amended)** The composition of claim 2, wherein the concentration of cholesterol is about 0.9%.
4. **(Original)** The composition of claim 2, further comprising an alcohol.
5. **(Currently amended)** The composition of claim 1, wherein the concentration of cardiolipin is between about 0.02 and 0.04%.
6. **(Currently amended)** The composition of claim 5, wherein the concentration of cardiolipin is about 0.03%.
7. **(Currently amended)** The composition of claim 1, wherein the concentration of 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine is between about 0.11 and 0.16%.
8. **(Currently amended)** The composition of claim 7, wherein the concentration of 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine is about 0.14%.
- 9 - 10. **(Cancelled)**
11. **(Original)** The composition of claim 4, wherein the alcohol is ethanol.
12. **(Previously presented)** A method for detecting anti-lipoidal antibodies in a

human comprising combining a biological sample from the human with a composition comprising tetramyristoyl cardiolipin 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine and detecting an immunocomplex formed between an anti-lipoidal antibody in the biological sample and the composition.

13. **(Original)** The method of claim 12, wherein the composition further comprises cholesterol and an alcohol.

14. **(Currently amended)** The method of claim 13, wherein the concentration of cholesterol in the composition is ~~about~~ 0.9%.

15. **(Original)** The method of claim 12, wherein the alcohol is ethanol.

16. **(Currently amended)** The method of claim 12, wherein the concentration of tetramyristoyl cardiolipin in the composition is between ~~about~~ 0.01 and 0.05%.

17. **(Currently amended)** The method of claim 12, wherein the concentration of 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine in the composition is between ~~about~~ 0.11 and 0.16%.

18 - 19. **(Cancelled)**

20. **(Previously presented)** The method of claim 12, wherein the detection of an immunocomplex is used to diagnose syphilis in the human.

21. **(Original)** The method of claim 12, wherein the immunocomplex is detected using a flocculation or agglutination test.

22. **(Currently amended)** The antigen composition of claim 1 comprising between ~~about~~ 0.02 and 0.04% tetramyristoyl cardiolipin, and between ~~about~~ 0.11 and 0.16% 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine.

23. **(Currently amended)** An antigen composition comprising between about 0.02 and 0.04% tetramyristoyl cardiolipin, between about 0.11 and 0.16% 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, about 0.9% cholesterol, and ethanol to volume.

24. **(Currently amended)** An antigen composition comprising about 0.03% tetramyristoyl cardiolipin, between about 0.11 and 0.16% 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, and about 0.9% natural cholesterol in absolute ethanol to volume.

25. **(Currently amended)** A method for detecting anti-lipoidal antibodies in a human comprising:

- (a) obtaining a biological sample from a human;
- (b) combining the biological sample with a composition comprising between about 0.02 and 0.04% tetramyristoyl cardiolipin, between about 0.11 and 0.16% 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, about 0.9% cholesterol, and ethanol to volume; and
- (c) detecting an immunocomplex formed between an antibody in the biological sample and the composition.

26. **(Previously presented)** The method of claim 25, wherein the detection of the immunocomplex is used to diagnose syphilis in the human.

27. **(Currently amended)** The method of claim 12, wherein the concentration of tetramyristoyl cardiolipin in the composition is between about 0.02 and 0.04%.